Asthma Medication Receives New Warning

Simple item page
dc.contributor.authorAschenbrenner, Diane S.
dc.contributor.departmentSandra R. Berman School of Nursing and Health Professionsen_US
dc.contributor.programNursingen_US
dc.date.accessioned2017-09-27T20:09:35Z
dc.date.available2017-09-27T20:09:35Z
dc.date.issued2015-01
dc.description.abstractThe labeling of omalizumab (Xolair), a drug used to treat allergic asthma, now carries a warning that its use may slightly increase the risk of cardiovascular complications. The drug may also pose an increased risk of inducing cancer.en_US
dc.description.urihttps://ezproxy.stevenson.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=rzh&AN=107811912&site=eds-live&scope=siteen_US
dc.format.extent2 pagesen_US
dc.genrejournal articlesen_US
dc.identifierdoi:10.13016/M27940V52
dc.identifier.citationAschenbrenner, D. S. (2015). Asthma medication receives new warning. AJN American Journal Of Nursing, 115(1), 22-23. doi:10.1097/01.NAJ.0000459621.92420.e0en_US
dc.identifier.urihttp://dx.doi.org/10.1097/01.NAJ.0000459621.92420.e0
dc.identifier.urihttp://hdl.handle.net/11603/5651
dc.language.isoen_USen_US
dc.publisherAmerican Journal of Nursingen_US
dc.titleAsthma Medication Receives New Warningen_US
dc.typeTexten_US

Files

License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Stevenson University Faculty and Staff Works